I-FDA ivuma i-ibrutinib kunyango lwe-graft-versus-host disease ( cGVHD ) ebantwaneni.

Ngomhla wama-24 ku-Agasti, i-2022, i-US Food and Drug Administration (FDA) ivume i-ibrutinib yonyango lwezigulane zabantwana abadala kunonyaka we-1 kunye nesifo esingapheliyo se-graft-versus-host disease ( cGVHD ) abafumana Emva kokungaphumeleli kwe-1- okanye i-multi-line. unyango lwenkqubo .Isalathiso esivunyiweyo ikakhulu kwizigulane zabantwana, kunye nereyithi yokuphendula iyonke ye-60% ngeveki ye-25, kunye nokwakhiwa kwamachiza kubandakanya ii-capsules, iipilisi kunye nokumiswa ngomlomo.

Ibrutinib, i-BTK inhibitor ephuhliswe yi-Pharmacyclics/Johnson & Johnson, i-kinase inhibitor evunyiweyo ngaphambili kunyango lwe-lymphocytic leukemia engapheliyo kunye ne-cell lymphoma kunye nezinye izifo.

I-Suntech igxile ekuphuhliseni nasekuveliseni i-pharmaceutical intermediates kunye ne-APIs usebenzisa iteknoloji eluhlaza.Okwangoku, inkampani yethu iphuhlise iimveliso ezintathu eziphakathi kwe-ibrutinib kuquka i-C AS: 143900-44-1 , C AS: 330792-70-6 , C AS: 330786-24-8 , zonke eziye zathengiswa kwimveliso yeefektri ze-GMP. .Phakathi kwabo, i-intermediate ye-C AS: 143900-44-1 iveliswa yi-chemical-enzymatic technology , enenzuzo yokukhusela okusingqongileyo okuluhlaza, ixabiso eliphantsi kunye nomgangatho ophezulu.Wamkelekile ukubonisana nokusebenzisana!